Altamira Therapeutics Ltd. (NASDAQ: CYTO) is -83.11% lower on its value in year-to-date trading and has touched a low of $0.73 and a high of $18.40 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The CYTO stock was last observed hovering at around $0.88 in the last trading session, with the day’s loss setting it -0.06% off its average median price target of $286.10 for the next 12 months. It is also 99.71% off the consensus price target high of $286.10 offered by 1 analysts, but current levels are 99.71% higher than the price target low of $286.10 for the same period.
Currently trading at $0.82, the stock is -13.28% and -30.85% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.39 million and changing -6.67% at the moment leaves the stock -81.28% off its SMA200. CYTO registered -94.68% loss for a year compared to 6-month loss of -85.72%. The firm has a 50-day simple moving average (SMA 50) of $42.86 and a 200-day simple moving average (SMA200) of -$0.51.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
Sponsored
The stock witnessed a -21.21% gain in the last 1 month and extending the period to 3 months gives it a -66.89%, and is -8.35% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 13.17% over the week and 13.79% over the month.
Altamira Therapeutics Ltd. (CYTO) has around 17 employees, a market worth around $0.93M and $1.40M in sales. Distance from 52-week low is 12.25% and -95.55% from its 52-week high.
Altamira Therapeutics Ltd. (CYTO) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Altamira Therapeutics Ltd. (CYTO) is a “Buy”. 1 analysts offering their recommendations for the stock, where 0 rate it as a Hold and 0 think it is a “Overweight”. 1 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Altamira Therapeutics Ltd. is expected to release its quarterly report on 08/17/2023.The EPS is expected to grow by 3.70% this year
Altamira Therapeutics Ltd. (CYTO) Top Institutional Holders
The shares outstanding are 6.99M, and float is at 6.91M with Short Float at 1.25%.
